Treatment
Novartis has been in the front ranks of a change in the treatment of malaria – by launching a new generation of antimalarial medicines known as artemisinin-based combination therapies, or ACTs, and later the first dispersible ACT tailored to meet the needs of children, the most vulnerable to malaria.